Dren Bio, a privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases, announced the closing of an oversubscribed $350 million private financing. The round was co-led by Juvia Group and Lightspeed Venture Partners, with participation from an expanded syndicate of new investors including Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, and OrbiMed. Participating existing investors included 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital, and ArrowMark Partners.